Home
Directory
MapJobsInsightsNewsLearn More
Claim Your Page

A discovery platform for biotech and life sciences, built to improve visibility, discovery, and connection across the ecosystem.

Follow Us

Explore

  • Directory
  • Categories
  • Map
  • Jobs
  • Insights
  • News
  • Learn More
  • Claim Your Page
  • Help & Support

Grow with Benchscope

  • Upgrade to Premium
  • Post a Job
  • Sponsor a Focus Area
  • Data Licensing
  • Press Enquiries

© 2026 Benchscope Ltd. All rights reserved.

Benchscope Ltd is registered in England and Wales. Company number: 16664850. Registered office: 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ.

Privacy PolicyTerms of ServiceCookie Policy
Directory

RNA Therapeutics Companies in the UK

RNA therapeutics companies develop medicines that use RNA molecules to alter protein production, silence disease-associated genes or deliver therapeutic instructions to cells. These approaches support the treatment of genetic disorders, cancer, infectious disease and other conditions.

This category includes companies working on:

  • Messenger RNA therapeutics and vaccines
  • Small interfering RNA and RNA interference
  • Antisense oligonucleotide medicines
  • RNA editing and gene-regulation technologies
  • RNA delivery systems and therapeutic development

Browse 63 UK RNA therapeutics companies below.

View full directory
RNA Therapeutics
Showing 41–60 of 63
Sort by

Alnylam Pharmaceuticals

South East England

European hub for RNAi therapeutics developer

Alnylam UK is the European operational headquarters of Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics. Based in Maidenhead, the UK office serves as Alnylam's primary base for European commercial operations, medical affairs, and regulatory activities. Alnylam has six approved RNAi medicines on…

BiopharmaDrug Discovery
View profile

Epitopea

CambridgeEast of England

RNA immunotherapies targeting novel tumour-specific antigens

Epitopea is a biopharma company developing off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Using spatial immunopeptidomics, genomics, and systems bioinformatics, the company identifies aberrantly-expressed tumour-specific antigens that are broadly shared across patients with the same tumour type.…

BiopharmaOncology
View profile

Vitarka Therapeutics

Sandwich (Kent)South East England

Non-viral intracellular drug delivery for solid tumours

Vitarka Therapeutics is a preclinical biotech company developing a non-viral drug delivery platform for targeted intracellular delivery of therapeutics to solid tumours. The technology uses pore-forming proteins to transport RNAi therapies and other payloads directly into cancer cells while limiting off-target…

BiopharmaDrug Delivery
View profile

AMPLY Discovery

BelfastNorthern Ireland

AI drug discovery platform developing novel biologics for cancer and AMR

AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to identify novel biologic drug candidates from natural biological diversity. The platform digitises biological molecules, identifies treatment…

BiotechDrug Discovery
View profile

MiNA Therapeutics

LondonGreater London

Small activating RNA therapeutics for gene upregulation and disease

MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of underactive genes by activating transcription rather than silencing it. The approach targets diseases driven by loss of normal gene…

BiopharmaDrug Discovery
View profile

RevoNA Bio

South East England

RNA-targeted drug discovery platform using machine learning

RevoNA Bio is a biotechnology company developing a high-throughput RNA biological platform for RNA-targeted drug discovery. The platform generates comprehensive RNA structural and functional datasets that feed a machine learning predictive engine, supporting hit identification, structure-activity relationship…

BiotechDrug Discovery
View profile

ScionxBio

CambridgeEast of England

AI-designed extended-expression RNA therapeutics for cardio-metabolic disease

ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months. Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling…

BiopharmaDrug Discovery
View profile

Harness Therapeutics

CambridgeEast of England

RNA-based therapeutics targeting neurodegenerative disease mechanisms

Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…

BiotechNeurology
View profile

AstraZeneca

CambridgeEast of England

Global pharmaceutical company developing medicines across major disease areas

AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…

BiopharmaOncology
View profile

Spliceor

CambridgeEast of England

RNA trans-splicing gene therapies for aggressive cancers

Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…

BiotechCell & Gene Therapy
View profile

Concinnity

GlasgowScotland

RNA-based gene control systems for safer cell and gene therapies

Concinnity Genetics is a biotechnology company developing RNA-based control systems that enable precise regulation of gene therapies after administration. Its technology allows therapeutic gene expression to be modulated or reduced in response to side effects or clinical need, addressing a fundamental safety…

BiotechCell & Gene Therapy
View profile

Sensible Biotechnologies

OxfordSouth East England

Cell-based platform for next-generation mRNA medicines

Sensible Biotechnologies is a biotechnology company developing a cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. Using engineered living cells and precision fermentation, the platform produces low-immunogenicity mRNA at scale, addressing fundamental limitations of conventional…

BiotechBioprocessing & Manufacturing
View profile

Cambridge RNA Technologies

CambridgeEast of England

Longer-lasting RNA medicines and immune-stealthed CAR-T research

Cambridge RNA Technologies develops experimental RNA platforms intended to extend the duration of therapeutic gene expression. Its research includes technologies for longer-lasting RNA medicines. In collaboration with Anglia Ruskin University, the company has investigated immune-stealth approaches for donor-derived…

BiotechCell & Gene Therapy
View profile

Elarna Bio

CambridgeEast of England

AI-guided RNA therapies for chronic metabolic diseases

Elarna Bio is a biotechnology company developing long-acting RNA therapeutics for chronic metabolic diseases. It combines AI-driven discovery with RNA engineering to improve the duration of therapeutic activity. The platform focuses on challenges associated with liver-targeted RNA treatments and is intended for…

BiotechAI & Machine Learning
View profile

SymphoRNA

StevenageEast of England

RNA therapeutics platform targeting multiple disease pathways

SymphoRNA is a company developing RNA medicines designed to address complex diseases by targeting multiple biological pathways simultaneously. Its platform uses a polysaccharide-based delivery system to enable combination RNA therapies, with the aim of achieving outcomes that single-target approaches cannot. Spun out…

BiotechMolecular Biology Tools
View profile

Sixfold Bioscience

LondonGreater London

Programmable RNA delivery platform targeting non-hepatic tissues

Sixfold Bioscience is a biotechnology company developing a programmable RNA-based delivery platform that exploits the body's natural extracellular RNA transport pathways to direct therapeutic RNA molecules to specific non-hepatic tissues and cell types. The platform uses computationally designed chemical modifications…

BiotechDrug Delivery
View profile

CamMed Therapeutics

StevenageEast of England

Novel mRNA technology platform for safer, faster vaccines

CamMed Therapeutics (Cambridge Medixine Ltd) is a preclinical biotechnology company developing a novel mRNA technology platform for vaccines and therapeutics. Inspired by natural biological phenomena, its engineered RNA molecules are designed to deliver safer, easier and faster medicines to the clinic while reducing…

BiopharmaDrug Discovery
View profile

Aqdot

CambridgeEast of England

Supramolecular encapsulation chemistry for controlled active delivery

Aqdot is a chemical technology company developing supramolecular systems for capturing, protecting and releasing active ingredients. Its encapsulation platform is commercially applied to odour removal and industrial formulations, while its research extends to RNA delivery systems for vaccines and cancer therapies. The…

Biotech (Industrial)Drug Delivery
View profile

SiSaf

South East England

Silicon-based RNA delivery platform for rare disease therapeutics

SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads. The platform addresses known limitations of conventional lipid…

BiopharmaDrug Delivery
View profile

XapHe

BelfastNorthern Ireland

Targeted nanoparticle formulations for nucleic acid delivery

XapHe is a biotechnology company developing peptide-based nanoparticles for therapeutic nucleic acid delivery. Its HAWC platform packages RNA and DNA payloads into formulations designed for cell entry and tissue targeting. The company supplies transfection kits and offers custom nanoparticle formulation services for…

BiotechDrug Delivery
View profile
Prev
1234
1234
Next

Benchscope

Sponsored

Sponsor your focus area

Reach buyers and partners across relevant directory pages and company profiles.

Premium Profiles

Upgrade your visibility on Benchscope

Promote your company with a premium or featured profile and stand out to biotech buyers, partners, and decision-makers exploring the directory.

Explore Premium